Zorcaine Injection, Solution
Product Images NDC 0362-0830

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zorcaine (NDC 0362-0830). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Septodont, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0362 0830 05

Packaging label for Zorcaine injection (articaine HCl and epinephrine) by Septodont, Inc. It is a submucosal injection solution containing 4% articaine hydrochloride (40 mg/mL) and epinephrine 1:100,000. The label indicates 50 single-dose cartridges, each 1.7 mL, with warnings and usage instructions primarily for dental use. The box is marked Rx only and includes manufacturer and barcode details.*

FDA Label Image

Structural Formula (Articaine HCl)

Chemical structure of Articaine Hydrochloride, the active ingredient in Zorcaine injection solution. The structure shows a thiophene ring with attached functional groups including methyl, ester, and amide groups, alongside the hydrochloride (HCl) component.*

FDA Label Image

Structural Formula (Epinephrine Bitartrate)

Chemical structure diagram showing the molecular formula of the active ingredient Articaine Hydrochloride and Epinephrine in Zorcaine injection solution.*

FDA Label Image

Table 2 Adverse Reactions

A data table listing adverse reactions with an incidence of 1% or greater in patients administered Zorcaine injection solution containing 1:100,000 epinephrine. The table shows body systems and specific reactions with corresponding incidence counts and percentages for a sample size of 882 patients.*

FDA Label Image

Table 3 Adverse Reactions

A data table titled 'Table 3: Adverse Reactions in Controlled Trials' showing the incidence of various adverse reactions in patients administered articaine hydrochloride 4% with epinephrine 1:200,000 versus ZORCAINE with epinephrine 1:100,000. The table lists reactions such as pain, headache, positive blood aspiration into syringe, swelling, trismus, nausea and emesis, sleepiness, numbness and tingling, palpitations, ear symptoms, and persistent cough with corresponding incidence percentages and patient counts for each drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.